FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914098214> ?p ?o ?g. }

• W2914098214 endingPage "888" @default.
• W2914098214 startingPage "877" @default.
• W2914098214 abstract "Background Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke. Methods We did an international, partial-factorial, open-label, blinded-endpoint trial of thrombolysis-eligible patients (age ≥18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg or more, who were screened at 110 sites in 15 countries. Eligible patients were randomly assigned (1:1, by means of a central, web-based program) within 6 h of stroke onset to receive intensive (target systolic blood pressure 130–140 mm Hg within 1 h) or guideline (target systolic blood pressure <180 mm Hg) blood pressure lowering treatment over 72 h. The primary outcome was functional status at 90 days measured by shift in modified Rankin scale scores, analysed with unadjusted ordinal logistic regression. The key safety outcome was any intracranial haemorrhage. Primary and safety outcome assessments were done in a blinded manner. Analyses were done on intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01422616. Findings Between March 3, 2012, and April 30, 2018, 2227 patients were randomly allocated to treatment groups. After exclusion of 31 patients because of missing consent or mistaken or duplicate randomisation, 2196 alteplase-eligible patients with acute ischaemic stroke were included: 1081 in the intensive group and 1115 in the guideline group, with 1466 (67·4%) administered a standard dose among the 2175 actually given intravenous alteplase. Median time from stroke onset to randomisation was 3·3 h (IQR 2·6–4·1). Mean systolic blood pressure over 24 h was 144·3 mm Hg (SD 10·2) in the intensive group and 149·8 mm Hg (12·0) in the guideline group (p<0·0001). Primary outcome data were available for 1072 patients in the intensive group and 1108 in the guideline group. Functional status (mRS score distribution) at 90 days did not differ between groups (unadjusted odds ratio [OR] 1·01, 95% CI 0·87–1·17, p=0·8702). Fewer patients in the intensive group (160 [14·8%] of 1081) than in the guideline group (209 [18·7%] of 1115) had any intracranial haemorrhage (OR 0·75, 0·60–0·94, p=0·0137). The number of patients with any serious adverse event did not differ significantly between the intensive group (210 [19·4%] of 1081) and the guideline group (245 [22·0%] of 1115; OR 0·86, 0·70–1·05, p=0·1412). There was no evidence of an interaction of intensive blood pressure lowering with dose (low vs standard) of alteplase with regard to the primary outcome. Interpretation Although intensive blood pressure lowering is safe, the observed reduction in intracranial haemorrhage did not lead to improved clinical outcome compared with guideline treatment. These results might not support a major shift towards this treatment being applied in those receiving alteplase for mild-to-moderate acute ischaemic stroke. Further research is required to define the underlying mechanisms of benefit and harm resulting from early intensive blood pressure lowering in this patient group. Funding National Health and Medical Research Council of Australia; UK Stroke Association; Ministry of Health and the National Council for Scientific and Technological Development of Brazil; Ministry for Health, Welfare, and Family Affairs of South Korea; Takeda. Systolic blood pressure of more than 185 mm Hg is a contraindication to thrombolytic treatment with intravenous alteplase in patients with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain. We assessed intensive blood pressure lowering compared with guideline-recommended blood pressure lowering in patients treated with alteplase for acute ischaemic stroke. We did an international, partial-factorial, open-label, blinded-endpoint trial of thrombolysis-eligible patients (age ≥18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg or more, who were screened at 110 sites in 15 countries. Eligible patients were randomly assigned (1:1, by means of a central, web-based program) within 6 h of stroke onset to receive intensive (target systolic blood pressure 130–140 mm Hg within 1 h) or guideline (target systolic blood pressure <180 mm Hg) blood pressure lowering treatment over 72 h. The primary outcome was functional status at 90 days measured by shift in modified Rankin scale scores, analysed with unadjusted ordinal logistic regression. The key safety outcome was any intracranial haemorrhage. Primary and safety outcome assessments were done in a blinded manner. Analyses were done on intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01422616. Between March 3, 2012, and April 30, 2018, 2227 patients were randomly allocated to treatment groups. After exclusion of 31 patients because of missing consent or mistaken or duplicate randomisation, 2196 alteplase-eligible patients with acute ischaemic stroke were included: 1081 in the intensive group and 1115 in the guideline group, with 1466 (67·4%) administered a standard dose among the 2175 actually given intravenous alteplase. Median time from stroke onset to randomisation was 3·3 h (IQR 2·6–4·1). Mean systolic blood pressure over 24 h was 144·3 mm Hg (SD 10·2) in the intensive group and 149·8 mm Hg (12·0) in the guideline group (p<0·0001). Primary outcome data were available for 1072 patients in the intensive group and 1108 in the guideline group. Functional status (mRS score distribution) at 90 days did not differ between groups (unadjusted odds ratio [OR] 1·01, 95% CI 0·87–1·17, p=0·8702). Fewer patients in the intensive group (160 [14·8%] of 1081) than in the guideline group (209 [18·7%] of 1115) had any intracranial haemorrhage (OR 0·75, 0·60–0·94, p=0·0137). The number of patients with any serious adverse event did not differ significantly between the intensive group (210 [19·4%] of 1081) and the guideline group (245 [22·0%] of 1115; OR 0·86, 0·70–1·05, p=0·1412). There was no evidence of an interaction of intensive blood pressure lowering with dose (low vs standard) of alteplase with regard to the primary outcome. Although intensive blood pressure lowering is safe, the observed reduction in intracranial haemorrhage did not lead to improved clinical outcome compared with guideline treatment. These results might not support a major shift towards this treatment being applied in those receiving alteplase for mild-to-moderate acute ischaemic stroke. Further research is required to define the underlying mechanisms of benefit and harm resulting from early intensive blood pressure lowering in this patient group." @default.
• W2914098214 created "2019-02-21" @default.
• W2914098214 creator A5004889443 @default.
• W2914098214 creator A5005538880 @default.
• W2914098214 creator A5011046660 @default.
• W2914098214 creator A5011996744 @default.
• W2914098214 creator A5016461885 @default.
• W2914098214 creator A5016546379 @default.
• W2914098214 creator A5016966768 @default.
• W2914098214 creator A5020373936 @default.
• W2914098214 creator A5020760868 @default.
• W2914098214 creator A5023948758 @default.
• W2914098214 creator A5025215914 @default.
• W2914098214 creator A5026830827 @default.
• W2914098214 creator A5027377669 @default.
• W2914098214 creator A5031431276 @default.
• W2914098214 creator A5034467582 @default.
• W2914098214 creator A5036471971 @default.
• W2914098214 creator A5037890696 @default.
• W2914098214 creator A5041602063 @default.
• W2914098214 creator A5041953394 @default.
• W2914098214 creator A5045343269 @default.
• W2914098214 creator A5047974613 @default.
• W2914098214 creator A5049798132 @default.
• W2914098214 creator A5052415437 @default.
• W2914098214 creator A5054651477 @default.
• W2914098214 creator A5055394217 @default.
• W2914098214 creator A5062097440 @default.
• W2914098214 creator A5063975444 @default.
• W2914098214 creator A5074548376 @default.
• W2914098214 creator A5078892748 @default.
• W2914098214 creator A5078963207 @default.
• W2914098214 creator A5079967649 @default.
• W2914098214 creator A5081985952 @default.
• W2914098214 creator A5083232394 @default.
• W2914098214 creator A5083719688 @default.
• W2914098214 creator A5084412014 @default.
• W2914098214 creator A5086855818 @default.
• W2914098214 date "2019-03-01" @default.
• W2914098214 modified "2023-10-14" @default.
• W2914098214 title "Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial" @default.
• W2914098214 cites W1775077741 @default.
• W2914098214 cites W1921891522 @default.
• W2914098214 cites W1974436531 @default.
• W2914098214 cites W1997064745 @default.
• W2914098214 cites W2059395281 @default.
• W2914098214 cites W2099220407 @default.
• W2914098214 cites W2114214167 @default.
• W2914098214 cites W2120509628 @default.
• W2914098214 cites W2138062462 @default.
• W2914098214 cites W2139540288 @default.
• W2914098214 cites W2141090888 @default.
• W2914098214 cites W2143004298 @default.
• W2914098214 cites W2153836018 @default.
• W2914098214 cites W2157978571 @default.
• W2914098214 cites W2159915255 @default.
• W2914098214 cites W2165568749 @default.
• W2914098214 cites W2213019825 @default.
• W2914098214 cites W2277258071 @default.
• W2914098214 cites W2350862887 @default.
• W2914098214 cites W2507190756 @default.
• W2914098214 cites W2606371730 @default.
• W2914098214 cites W2740053016 @default.
• W2914098214 doi "https://doi.org/10.1016/s0140-6736(19)30038-8" @default.
• W2914098214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30739745" @default.
• W2914098214 hasPublicationYear "2019" @default.
• W2914098214 type Work @default.
• W2914098214 sameAs 2914098214 @default.
• W2914098214 citedByCount "159" @default.
• W2914098214 countsByYear W29140982142019 @default.
• W2914098214 countsByYear W29140982142020 @default.
• W2914098214 countsByYear W29140982142021 @default.
• W2914098214 countsByYear W29140982142022 @default.
• W2914098214 countsByYear W29140982142023 @default.
• W2914098214 crossrefType "journal-article" @default.
• W2914098214 hasAuthorship W2914098214A5004889443 @default.
• W2914098214 hasAuthorship W2914098214A5005538880 @default.
• W2914098214 hasAuthorship W2914098214A5011046660 @default.
• W2914098214 hasAuthorship W2914098214A5011996744 @default.
• W2914098214 hasAuthorship W2914098214A5016461885 @default.
• W2914098214 hasAuthorship W2914098214A5016546379 @default.
• W2914098214 hasAuthorship W2914098214A5016966768 @default.
• W2914098214 hasAuthorship W2914098214A5020373936 @default.
• W2914098214 hasAuthorship W2914098214A5020760868 @default.
• W2914098214 hasAuthorship W2914098214A5023948758 @default.
• W2914098214 hasAuthorship W2914098214A5025215914 @default.
• W2914098214 hasAuthorship W2914098214A5026830827 @default.
• W2914098214 hasAuthorship W2914098214A5027377669 @default.
• W2914098214 hasAuthorship W2914098214A5031431276 @default.
• W2914098214 hasAuthorship W2914098214A5034467582 @default.
• W2914098214 hasAuthorship W2914098214A5036471971 @default.
• W2914098214 hasAuthorship W2914098214A5037890696 @default.
• W2914098214 hasAuthorship W2914098214A5041602063 @default.
• W2914098214 hasAuthorship W2914098214A5041953394 @default.
• W2914098214 hasAuthorship W2914098214A5045343269 @default.
• W2914098214 hasAuthorship W2914098214A5047974613 @default.
• W2914098214 hasAuthorship W2914098214A5049798132 @default.
• W2914098214 hasAuthorship W2914098214A5052415437 @default.

• next